jRCT2031220049进行中（未招募）不适用
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen K.K.
- 入组人数
- 516
- 主要终点
- Overall Survival
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 100age old under（—）
- 性别
- All
入选标准
- •Adults with histologically documented unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer not amenable to curative therapy
- •Fibroblast growth factor receptor 2b (FGFR2b) >= 10% 2+/3+ tumor cell staining as determined by centrally performed immunohistochemistry (IHC) testing, based on tumor sample either archival (obtained within 6 months/180 days prior to signing pre-screening informed consent) or a fresh biopsy
- •Eastern Cooperative Oncology Group (ECOG) less than or equal to 1
- •Measurable disease or non-measurable, but evaluable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) V 1.1
- •Participant has no contraindications to mFOLFOX6 chemotherapy
- •Adequate organ and bone marrow function:
- •absolute neutrophil count greater than or equal to 1.5 times 10^9/L
- •platelet count greater than or equal to 100 times 10^9/L
- •hemoglobin >= 9 g/dL without red blood cell (RBC) transfusion within 7 days prior to the first dose of study treatment
- •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times the upper limit of normal (ULN) (or less than 5 times ULN if liver involvement). Total bilirubin less than 1.5 times ULN (or less than 2 times ULN if liver involvement); with the exception of participants with Gilbert's disease)
- •calculated or measured creatinine clearance (CrCl) of >= 30 mL/minute calculated using the formula of Cockcroft and Gault ([140 - Age]) x Mass [kg]/[72 x Creatinine mg/dL]) (x 0.85 if female)
- •international normalized ratio (INR) or prothrombin time (PT) less than 1.5 times ULN except for participants receiving anticoagulation, who must be on a stable dose of anticoagulant therapy for 6 weeks prior to enrollment
排除标准
- •Prior treatment for metastatic or unresectable disease (Note: prior adjuvant, neo-adjuvant and peri-operative therapy is allowed if completed more than 6 months prior to first dose of study treatment)
- •Prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast growth factor receptor (FGF-FGFR) pathway
- •Known human epidermal growth factor receptor 2 (HER2) positive
- •Untreated or symptomatic central nervous system (CNS) disease or brain metastases
- •Peripheral sensory neuropathy greater than or equal to Grade 2
- •Clinically significant cardiac disease
- •Other malignancy within the last 2 years (exceptions for definitively treated disease)
- •Chronic or systemic ophthalmological disorders
- •Major surgery or other investigational study within 28 days prior to first dose of study treatment
- •Palliative radiotherapy within 14 days prior to the first dose of study treatment
- •Evidence of or recent history (within 6 months) of corneal defects, corneal ulcerations, keratitis, or keratoconus, history of corneal transplant, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer.
结局指标
主要结局
Overall Survival
时间窗: Up to approximately 3.5 years
Overall survival in FGFR2b >= 10% 2+/3+ tumor cell staining participants
次要结局
- Progression-free Survival (PFS) in FGFR2b >= 10% 2+/3+ tumor cell staining participants(Up to approximately 3.5 years)
- Objective Response Rate (ORR) in FGFR2b >= 10% 2+/3+ tumor cell staining participants(Up to approximately 3.5 years)
- Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE)(Up to approximately 3.5 years)
- Overall Survival in all randomized participants(Up to approximately 3.5 years)
- Progression-free Survival (PFS) in all randomized participants(Up to approximately 3.5 years)
- Objective Response Rate (ORR) in all randomized participants(Up to approximately 3.5 years)
- Duration of Response (DOR) in FGFR2b >= 10% 2+/3+ tumor cell staining participants(Up to approximately 3.5 years)
- Disease Control Rate in FGFR2b >= 10% 2+/3+ tumor cell staining participants(Up to approximately 3.5 years)
- Mean Subjective Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)(Up to approximately 3.5 years)
- Change from Baseline Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)(Baseline up to approximately 3.5 years)
- Stomach Cancer Related Symptom Mean Subjective Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22)(Up to approximately 3.5 years)
- Change from Baseline in Stomach Cancer Related Symptom Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22)(Baseline up to approximately 3.5 years)
- Mean Subjective Score in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L)(Up to approximately 3.5 years)
- Change from Baseline of Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L)(Baseline up to approximately 3.5 years)
- Time to Deterioration in Stomach Cancer Related Symptom Score as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach (EORTC-QLQ-STO22)(Up to approximately 3.5 years)
- Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQC30) Score(Up to approximately 3.5 years)
- Time to Deterioration in Visual Analogue Scale (VAS) as Measured by the EuroQol 5-dimensional 5-levels (EQ-5D-5L) Score(Up to approximately 3.5 years)
- Time to Deterioration in Physical Function Score as Measured by a Subscale of European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)(Day 1 up to approximately 3.5 years)
研究者
相似试验
招募中
1 期
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionMedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864CTIS2023-505458-16-00Amgen Inc.528
进行中（未招募）
1 期
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alonentreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b OverexpressionMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.1Level: LLTClassification code 10084227Term: Gastroesophageal junction cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003477-61-HUAmgen Inc.702
招募中
3 期
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction CancerGastric Cancer , Gastroesophageal Junction AdenocarcinomaJPRN-jRCT2031210669Kaneda Hirokazu528
进行中（未招募）
1 期
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab AloneEUCTR2021-003477-61-BEAmgen Inc.528
进行中（未招募）
1 期
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab AloneEUCTR2021-003477-61-ESAmgen Inc.702